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INTRODUCTION
Although phototherapy has been used for the treatment
of neonatal jaundice for more than 4 decades, the most effi-
cacious phototherapy method with the least side effects has
not been developed yet (1-3). Its efficacy is dependent on the
color (wavelength) and intensity (irradiance) of the light emit-
ted during phototherapy, the exposed body surface area, and
the duration of exposure (2, 4-6). The currently available pho-
totherapy devices such as fluorescent tubes, halogen spotlights
and fiberoptic blankets have many disadvantages including
high heat production and unstable broad wavelength light
output (1, 7, 8). In cases of severe or rapidly increasing neona-
tal jaundice, it is important to institute intensive photother-
apy to decrease the bilirubin levels as soon as possible to reduce
the need for exchange transfusion and the risk of kernicterus
(9-11). However, conventionally used phototherapy may be
less effective, thereby increasing the risk of bilirubin-induced
neurotoxicity (2, 4, 11).
Recently, high intensity gallium nitride light emitting
diodes (LEDs) have been developed (12, 13), and studied as
possible light sources for the phototherapy of neonatal jaun-
dice (14). Blue LEDs emit a high intensity narrow band of
blue light overlapping the peak spectrum of bilirubin break-
down (14), resulting in potentially shorter treatment times
(15, 16). LEDs are also power efficient, light in weight, pro-
duce less heat, and have a longer lifetime (12-14). These uni-
que characteristics of LEDs make them very optimal light
sources for phototherapy devices. Despite these potential ben-
efits and substantial versatility of this device, two recent clini-
cal trials of blue gallium nitride LED were not found to be
of higher efficacy when applied using relatively low irradi-
ances levels (17, 18). These results suggest that besides the
color (wavelength), the dose (irradiance) of light is also very
important in determining the effectiveness of phototherapy
(2, 4-6, 16). As LED devices could generate significantly high-
er light irradiance levels compared to all currently available
conventional phototherapy units (14), much higher irradi-
ance levels are likely to be used clinically in the future. There-
fore, in the present study, we developed a prototype blue LED
phototherapy unit with high intensity, and compared its effi-
cacy to that of commercially used halogen quartz photother-
apy device by measuring both in vitro and in vivo bilirubin
photodegradation.
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In vitro and in vivo Efficacy of New Blue Light Emitting Diode 
Phototherapy Compared to Conventional Halogen Quartz 
Phototherapy for Neonatal Jaundice
High intensity light emitting diodes (LEDs) are being studied as possible light
sources for the phototherapy of neonatal jaundice, as they can emit high intensity
light of narrow wavelength band in the blue region of the visible light spectrum cor-
responding to the spectrum of maximal bilirubin absorption. We developed a pro-
totype blue gallium nitride LED phototherapy unit with high intensity, and compared
its efficacy to commercially used halogen quartz phototherapy device by measur-
ing both in vitro and in vivo bilirubin photodegradation. The prototype device with
two focused arrays, each with 500 blue LEDs, generated greater irradiance than
the conventional device tested. The LED device showed a significantly higher effi-
cacy of bilirubin photodegradation than the conventional phototherapy in both in
vitro experiment using microhematocrit tubes (44±7% vs. 35±2%) and in vivo
experiment using Gunn rats (30±9% vs. 16±8%). We conclude that high intensi-
ty blue LED device was much more effective than conventional phototherapy of
both in vitro and in vivo bilirubin photodegradation. Further studies will be neces-
sary to prove its clinical efficacy.
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MATERIALS AND METHODS
Phototherapy unit
A prototype of high intensity gallium nitride blue LED
phototherapy unit was developed and custom built by the
Department of Pediatrics and Biomedical Engineering at the
Samsung Medical Center, Sungkyunkwan University School
of Medicine. High intensity blue LEDs (HLBB-L55B, Nis-
sitronics Korea Inc., Seoul, Korea) had a dominant wavelength
at 465-470 nm, and the overhead device had two focused
arrays, each array equipped with 500 LEDs (Fig. 1). For con-
ventional phototherapy, halogen quartz phototherapy device
(Model: 6600-0084-900, Ohmeda Medical Co., MD, U.S.A.)
was used. As halogen lamps could incur the risk of burn when
positioned closer to the infant, phototherapy was administered
45 cm apart in accordance with the manufacturer’s recom-
mendation. At that distance, irradiance was measured with
a phototherapy radiometer (BiliBlanket Meter II, Ohmeda
Medical Co., MD, U.S.A.), with peak sensitivity at 450 nm,
and illuminance was measured with an Illuminance Meter,
TL-1 Minolta (Minolta Camera Co., Tokyo, Japan). The in
vitro results do not necessarily reflect its in vivo efficacy due
to confounding variables including poor skin penetration of
blue light spectrum (14-16). We therefore conducted both in
vitro and in vivo experiment to determine the bilirubin degra-
dation efficacy of LED device in the present study. 
In vitro experiment
Bilirubin (Sigma Chemical Co., MO, U.S.A.) was dissolved
in a buffer solution containing 18.5 vol% 0.1 N NaOH, 44.5
vol% human albumin (5%) and 37 vol% 0.055 M Na2HPO4,
with the final concentration and pH adjusted to 20 mg/dL
and 7.4 respectively. In each group, ten microhematocrit tubes
containing 100  L of the bilirubin solution per tube, was
placed horizontally on a black non-reflective background, and
exposed to each phototherapy light at 45 cm distance for 5
hr at room temperature. In vitro photodegradation of biliru-
bin (%) was calculated as the difference between bilirubin
concentrations at before and after exposure to the photother-
apy divided by the bilirubin concentration at before exposure
to the phototherapy times 100. Bilirubin concentration was
measured with Bilirubin Tester (Wako Pure Chemical Indus-
tries Ltd., Osaka, Japan).
In vivo experiment 
For in vivo experiment, Gunn rats were purchased from
Harlan Sprague Dawley, Inc. (Indianapolis, IN, U.S.A.). Twen-
ty of 8-day old jaundiced (jj) Gunn rats were randomly divid-
ed into two groups, and exposed to each phototherapy light
at 45 cm distance for 5 hr at room temperature. In vivo biliru-
bin degradation (%) was also calculated as the difference bet-
ween serum bilirubin concentrations of Gunn rats at before
and after exposure to the phototherapy divided by the serum
bilirubin concentration  at before exposure to the photother-
apy times 100.
Statistical analysis
Statistical analysis was performed by Student’s t test. The
data are presented as mean±standard deviation. A p-value
of <0.05 was considered significant.
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Fig. 2. Comparison of both in vitro and in vivo efficacy of bilirubin
photodegradation between the blue LED and conventional pho-
totherapy unit. Data are expressed as mean±standard deviation.
a: p<0.05 compared to conventional phototherapy.
a
a
Fig. 1. A prototype phototherapy device made of two focused
arrays, each with 500 high intensity blue gallium nitride light emit-
ting diodes (LEDs).RESULTS
Mean irradiance of blue LED and conventional photother-
apy unit at 45 cm distance was 75 and 23  W/cm2/nm, and
illuminance was 680 and 1999 foot candle, respectively.
Bilirubin photodegradation of blue LED device was sig-
nificantly higher than conventional phototherapy in both in
vitro (44±7% vs. 35±2%) and in vivo (30±9% vs. 16
±8%) experiment (Fig. 2).
DISCUSSION 
In the present study, high intensity gallium nitride blue
LED phototherapy was more effective than conventional halo-
gen quartz phototherapy in both in vitro and in vivo biliru-
bin photodegradation. More rapid breakdown of bilirubin
with the use of more efficient LED phototherapy devices would
shorten the treatment times of neonatal jaundice (15, 16), and
ultimately improve the prognosis of severe neonatal hyper-
bilirubinemia by reducing the need for exchange transfusion
and minimizing the risk of bilirubin neurotoxicity (2, 4, 11). 
The optimum phototherapy method with the least side
effects has not been developed yet (1-3). The color (wavelength)
and intensity (irradiance) of the light emitted during pho-
totherapy are two major factors determining its efficacy (2,
4-6). Blue LEDs used for light sources of phototherapy in the
present study would be more effective than day light because
they emit a high intensity narrow band of blue light corre-
sponding to the peak absorption wavelength at which biliru-
bin is broken down (14). Furthermore, as LEDs emit no sig-
nificant ultraviolet or infrared light, they would reduce the
potential risk of DNA damage (8) or fluid loss (7). However,
two recent clinical trials of blue gallium nitride LED device
using comparable light intensity were not found to be of high-
er efficacy than the conventional phototherapy (17, 18). In
contrast, gallium nitride blue LED phototherapy was observed
to be more effective than conventional phototherapy in both
in vitro and in vivo bilirubin photodegradation in the present
study. As the irradiance and illuminance of our LED device
was nearly three times higher and three times less than the
conventional phototherapy respectively, not the broad light
intensity (illuminance) but the specific light intensity match-
ing the bilirubin absorption spectrum (irradiance) seems to
correlate with the magnitude of bilirubin photodegradation
(6, 16). Taken together, these findings suggest that besides
the wavelength, the intensity of light (irradiance) emitted
during phototherapy is also very important for its best effi-
cacy (2, 4-6, 16). 
The dose of phototherapy light is the product of irradiance,
surface area exposed, and duration of exposure (2, 4-6, 16).
Irradiance depends not only on the power of the light source
but also on the distance from the source (2, 4, 5). LEDs can
deliver much higher doses of light than any of the conven-
tional devices as they generate greater irradiance (14), and
can be placed very close to the skin due to less heat produc-
tion in contrast to halogen or fluorescent lights (1, 7). Fur-
thermore, such direct contact LEDs in the form of mattress-
es, pads or jackets of any size and shape could cover a larger
surface area than conventional devices, leading to more effi-
cient and convenient phototherapy and abrogating the need
for eye patches (2). Therefore, LED devices could markedly
improve the efficacy and safety of phototherapy (14). 
Tan (5, 19) demonstrated a dose response relationship with
increased intensity of phototherapy resulting in greater res-
ponses. However, the rate of bilirubin decline progressively
decreased with increasing irradiance until a saturation point
of 30-40  W/cm2/nm in the 425 to 475 nm range was reach-
ed, beyond which an increase in the irradiance produced no
added efficacy. At the saturation point, a bilirubin decline of
40 to 50% in 24 hr was achieved (19). However, given that
the conversion of bilirubin to excretable photoproducts is
partly irreversible and follows first order kinetics (14, 15), it
is not certain whether a saturation point suggested by Tan
really exists. Our data of more effective bilirubin degradation
with blue LEDs well above the saturation point of irradiance
also contradict the concept of the saturation point. As LED
phototherapy devices can provide significantly higher irra-
diance levels compared to all currently available convention-
al systems (14), further studies will be necessary to clarify this.
In addition to the features mentioned above, LEDs have
several advantages not found in conventional devices such as
light weight, compact size, high energy efficiency, use of low
voltage battery power, extremely long life, the ability to be
focused with a lens or through spatial orientation and no glass
parts (2, 12-14). These features make the LED devices ideal
light sources for phototherapy during transport or at home.
Furthermore, as LEDs use direct current, the typical flicker-
ing glare that may be responsible for the untoward symptoms
of headache, nausea and dizziness, reported with the use of
conventional blue fluorescent lamps (11), is absent, thereby
reducing nursing staff discomfort (17, 18). 
In summary, a blue LED phototherapy unit with higher
irradiance levels showed higher efficacy of both in vitro and
in vivo bilirubin photodegradation compared to that of com-
mercially used halogen quartz phototherapy device. As LED
devices can provide much higher irradiance, and thus greater
efficacy, they can be ideal light sources for the phototherapy
of neonatal jaundice. Additional studies will be necessary to
prove its clinical efficacy. 
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